(ALGN) Align Technology - Overview
Stock: Clear Aligners, Intraoral Scanners, CAD/CAM Software, Whitening System
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 42.7% |
| Relative Tail Risk | -11.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.05 |
| Alpha | -31.69 |
| Character TTM | |
|---|---|
| Beta | 1.238 |
| Beta Downside | 0.672 |
| Drawdowns 3y | |
|---|---|
| Max DD | 67.59% |
| CAGR/Max DD | -0.24 |
Description: ALGN Align Technology January 02, 2026
Align Technology (NASDAQ: ALGN) operates two core segments: the Clear Aligner segment, which markets the Invisalign family of clear aligners, Vivera retainers, and related orthodontic accessories for patients ranging from children to adults; and the Imaging Systems & CAD/CAM Services segment, which sells iTero intra-oral scanners, exocad design software, and a suite of digital workflow tools for restorative and orthodontic practices.
In its most recent fiscal year (2023), Align reported revenue of roughly $5.1 billion, a year-over-year increase of about 20 %, and an adjusted operating margin near 22 %. The company shipped roughly 12 million Invisalign aligners and over 1.2 million iTero scanners, reflecting continued market penetration and strong repeat-purchase rates among dental professionals.
Key growth drivers include the expanding global demand for cosmetic orthodontics (the market is projected to grow at a CAGR of ~7 % through 2028), accelerating adoption of digital dentistry platforms that improve treatment efficiency, and macro-level trends such as higher discretionary spending in developed economies and an aging population seeking aesthetic dental solutions.
For a deeper, data-driven look at ALGN’s valuation and scenario analysis, the ValueRay platform provides a concise, research-ready overview.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 410.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 3.09 > 1.0 |
| NWC/Revenue: 17.26% < 20% (prev 11.36%; Δ 5.90% < -1%) |
| CFO/TA 0.11 > 3% & CFO 656.1m > Net Income 410.4m |
| Net Debt (-1.01b) to EBITDA (685.4m): -1.48 < 3 |
| Current Ratio: 1.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.8m) vs 12m ago -3.64% < -2% |
| Gross Margin: 67.19% > 18% (prev 0.70%; Δ 6649 % > 0.5%) |
| Asset Turnover: 64.83% > 50% (prev 64.35%; Δ 0.48% > 0%) |
| Interest Coverage Ratio: 252.3 > 6 (EBITDA TTM 685.4m / Interest Expense TTM 1.56m) |
Altman Z'' 4.37
| A: 0.11 (Total Current Assets 2.62b - Total Current Liabilities 1.92b) / Total Assets 6.23b |
| B: 0.39 (Retained Earnings 2.42b / Total Assets 6.23b) |
| C: 0.06 (EBIT TTM 394.6m / Avg Total Assets 6.22b) |
| D: 1.85 (Book Value of Equity 4.05b / Total Liabilities 2.18b) |
| Altman-Z'' Score: 4.37 = AA |
Beneish M -2.96
| DSRI: 1.06 (Receivables 1.10b/1.03b, Revenue 4.03b/4.00b) |
| GMI: 1.04 (GM 67.19% / 70.00%) |
| AQI: 1.01 (AQ_t 0.38 / AQ_t-1 0.38) |
| SGI: 1.01 (Revenue 4.03b / 4.00b) |
| TATA: -0.04 (NI 410.4m - CFO 656.1m) / TA 6.23b) |
| Beneish M-Score: -2.96 (Cap -4..+1) = A |
What is the price of ALGN shares?
Over the past week, the price has changed by +15.07%, over one month by +11.89%, over three months by +40.28% and over the past year by -14.09%.
Is ALGN a buy, sell or hold?
- StrongBuy: 8
- Buy: 3
- Hold: 6
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the ALGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 194.1 | 3.4% |
| Analysts Target Price | 194.1 | 3.4% |
| ValueRay Target Price | 184.8 | -1.5% |
ALGN Fundamental Data Overview February 07, 2026
P/E Forward = 15.0376
P/S = 3.1964
P/B = 2.8582
P/EG = 0.9643
Revenue TTM = 4.03b USD
EBIT TTM = 394.6m USD
EBITDA TTM = 685.4m USD
Long Term Debt = unknown (none)
Short Term Debt = 34.0m USD (from shortTermDebt, two quarters ago)
Debt = 82.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.01b USD (from netDebt column, last quarter)
Enterprise Value = 11.72b USD (12.73b + Debt 82.5m - CCE 1.09b)
Interest Coverage Ratio = 252.3 (Ebit TTM 394.6m / Interest Expense TTM 1.56m)
EV/FCF = 20.68x (Enterprise Value 11.72b / FCF TTM 566.6m)
FCF Yield = 4.84% (FCF TTM 566.6m / Enterprise Value 11.72b)
FCF Margin = 14.04% (FCF TTM 566.6m / Revenue TTM 4.03b)
Net Margin = 10.17% (Net Income TTM 410.4m / Revenue TTM 4.03b)
Gross Margin = 67.19% ((Revenue TTM 4.03b - Cost of Revenue TTM 1.32b) / Revenue TTM)
Gross Margin QoQ = 65.26% (prev 64.20%)
Tobins Q-Ratio = 1.88 (Enterprise Value 11.72b / Total Assets 6.23b)
Interest Expense / Debt = 1.90% (Interest Expense 1.56m / Debt 82.5m)
Taxrate = 23.12% (40.8m / 176.6m)
NOPAT = 303.4m (EBIT 394.6m * (1 - 23.12%))
Current Ratio = 1.36 (Total Current Assets 2.62b / Total Current Liabilities 1.92b)
Debt / Equity = 0.02 (Debt 82.5m / totalStockholderEquity, last quarter 4.05b)
Debt / EBITDA = -1.48 (Net Debt -1.01b / EBITDA 685.4m)
Debt / FCF = -1.79 (Net Debt -1.01b / FCF TTM 566.6m)
Total Stockholder Equity = 3.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.59% (Net Income 410.4m / Total Assets 6.23b)
RoE = 10.45% (Net Income TTM 410.4m / Total Stockholder Equity 3.93b)
RoCE = 9.15% (EBIT 394.6m / Capital Employed (Total Assets 6.23b - Current Liab 1.92b))
RoIC = 7.80% (NOPAT 303.4m / Invested Capital 3.89b)
WACC = 10.42% (E(12.73b)/V(12.81b) * Re(10.48%) + D(82.5m)/V(12.81b) * Rd(1.90%) * (1-Tc(0.23)))
Discount Rate = 10.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.70%
[DCF Debug] Terminal Value 72.07% ; FCFF base≈489.2m ; Y1≈558.3m ; Y5≈769.9m
Fair Price DCF = 138.2 (EV 8.90b - Net Debt -1.01b = Equity 9.92b / Shares 71.7m; r=10.42% [WACC]; 5y FCF grow 16.51% → 2.90% )
EPS Correlation: 68.02 | EPS CAGR: 12.29% | SUE: 2.88 | # QB: 2
Revenue Correlation: 66.90 | Revenue CAGR: 1.98% | SUE: -0.20 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.26 | Chg30d=-0.171 | Revisions Net=+0 | Analysts=10
EPS current Year (2026-12-31): EPS=11.28 | Chg30d=+0.297 | Revisions Net=+3 | Growth EPS=+7.4% | Growth Revenue=+3.8%
EPS next Year (2027-12-31): EPS=12.21 | Chg30d=+0.297 | Revisions Net=+2 | Growth EPS=+8.2% | Growth Revenue=+4.7%